Beijing: China’s capital, approved a groundbreaking homegrown flu drug. On June 10, the National Medical Products Administration authorised peramivir, the first influenza drug in the world, to target the PB2 protein in the flu virus’s RNA polymerase.
This innovative medicine, developed jointly by Raynovent in Guangzhou, the First Affiliated Hospital of Guangzhou Medical University, and leading respiratory disease research institutions, offers a new treatment option for adult patients with uncomplicated influenza A.
The oral drug comes in 0.6-gram tablets and is taken three times daily for five days. According to China Daily, peramivir demonstrates rapid, potent effects with low resistance and represents a significant Chinese contribution to the global fight against influenza.
Influenza affects around 1 billion people globally each year, and up to 650,000 people die. This approval marks a significant step in diversifying the global flu treatment portfolio and highlights China’s growing role in pharmaceutical innovation.
